Frequently Asked Questions
  • CANLYTx is a comprehensive Whole Exome based Genomic test that examines your tumour DNA to uncover the complex genomic alterations that cause your cancer. Our molecular analysis is performed on your genomic data to recommend a treatment plan that is tailored to your unique tumour. CANLYTx performs “Molecular Docking Studies” on the recommended therapies to further select the most suitable option.

  • Whole Exome Sequencing (WES), is performed in the Genomics laboratory located in California, USA our partner labs for Next Generation Sequencing (NGS) services. This laboratory is CAP and CLIA certified. Bioinformatic Analysis happens across our locations globally.

  • Formalin-fixed paraffin embedded (FFPE) specimens*
    **Whole Peripheral Blood (when no tissue sample is available)

    *subject to fulfilling the criteria
    ** TAT & cost will vary

  1. Histopathology report
  2. Pathology report
  3. Clinical diagnosis & summary
  4. If currently out patient, the last clinical discharge summary
  5. Kyvor patient consent form and patient information signed by the patient or the patient’s care taker

  • Our estimated turn-around-time is 4-5 weeks once samples are available in the laboratory.

  • The combination of different sciences involved in the analysis, and complexity of the data being analysed requires stringent Quality Control and Quality Assurance processes to be complied with to ensure the accuracy of the findings.

  • The cost of the test will be shared when you get in touch with us. Accepted modes of payment is online or cheque, details of which will be shared with you based on your location.
    If your doctor recommends the test, some insurance providers will reimburse the cost of the test. For specific locations, we have EMI options available and you can check with us on info@kyvorgenomics.com for availability in your location.

  • All Solid tumours, for example Breast, Lung, Colorectal, Head and Neck to mention a few.

  • CANLYTx is recommended once the doctor confirms your diagnosis for Cancer. It will help your doctor to plan a suitable therapy/treatment regimen.

  • Every patient has unique genomic alterations and therefore the results will vary from patient to patient. The test will match your genomic alterations and categorize the suitable therapy as per the guidelines :
    1. Suitable for the specific tumour type and guideline approved
    2. Not suitable but guideline approved ( genomic alteration is not found in the tumour)
    3. Suitable for other tumour type
    4. A clinical trial evaluating therapies which may work by targeting the alterations

  • No two cancers are alike and No two treatments are alike. The differences in cancers is due to the unique genetic characteristics. Cancer can be from the same organ, but no two cancers are alike. Similarly because of the genetic differences,no two treatments can be the same as each person responds differently.

  • Genomic testing refers to the alterations in your DNA that you have acquired over a period of time that impact the normal functioning of the cells. Acquired alterations are responsible for majority of the cancers and impact the progression of the cancer and also the response to therapy/treatments.

  • Whole Exome is the functional part of the genome that is responsible for the normal functioning of the human body. It is comprised of circa 23,000 genes performing different functions. Analysis of this whole exome allows detection of various genomic alterations directly or indirectly responsible for cancer and also responses to therapy/treatment.
    Single gene/hotspot/comprehensive panel is the analysis of a specific set of genes. This type of targeted or specific analysis cannot detect the latest or novel and rare genomic alterations that may be the causative factor of your cancer or your response to therapy.